Sanofi Turns The Screws On Genzyme
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi-Aventis goes public with a $69-per-share offer for Genzyme, while the biotech rebuffs the offer as "opportunistic."
You may also be interested in...
Following Through On Prior Plan, Genzyme Sells Off Genetic Testing Unit
Sale of Genzyme Genetics for $925 million to LabCorp seen as enhancing the biotech's potential purchase value.
Following Through On Prior Plan, Genzyme Sells Off Genetic Testing Unit
Sale of Genzyme Genetics for $925 million to LabCorp seen as enhancing the biotech's potential purchase value.
Sanofi And Genzyme: Do Big Pharmas And Orphan Drugs Fit Together?
Big pharmas from Pfizer to GlaxoSmithKline are expanding their initiatives in niche disease areas, but if Sanofi-Aventis acquires Genzyme as it hopes, the French drug maker could soon emerge as an orphan drug leader